| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5508287 | Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 2017 | 9 Pages |
•A new class of steroidal inhibitors-mechanism-based suicide substrates- to treat sleeping sickness was studied.•26,27-Dehydrolanosterol inhibits ergosterol biosynthesis and growth of Trypanosoma brucei.•26,27-Dehydrolanosterol is a pro-drug converted in vivo to a suicide substrate of Tb-sterol methyltransferase.•Kinetic and chemical mechanism of enzymic inactivation by suicide substrate is reported.
A new class of steroidal therapeutics based on phylogenetic-guided design of covalent inhibitors that target parasite-specific enzymes of ergosterol biosynthesis is shown to prevent growth of the protozoan-Trypanosoma brucei, responsible for sleeping sickness. In the presence of approximately 15 ± 5 μM 26,27-dehydrolanosterol, T. brucei procyclic or blood stream form growth is inhibited by 50%. This compound is actively converted by the parasite to an acceptable substrate of sterol C24-methyl transferase (SMT) that upon position-specific side chain methylation at C26 inactivates the enzyme. Treated cells show dose-dependent depletion of ergosterol and other 24β-methyl sterols with no accumulation of intermediates in contradistinction to profiles typical of tight binding inhibitor treatments to azoles showing loss of ergosterol accompanied by accumulation of toxic 14-methyl sterols. HEK cells accumulate 26,27-dehydrolanosterol without effect on cholesterol biosynthesis. During exposure of cloned TbSMT to 26,27-dehydrozymosterol, the enzyme is gradually inactivated (kcat/kinact = 0.13 min− 1/0.08 min− 1; partition ratio of 1.6) while 26,27-dehydrolanosterol binds nonproductively. GC–MS analysis of the turnover product and bound intermediate released as a C26-methylated diol (C3-OH and C24-OH) confirmed substrate recognition and covalent binding to TbSMT. This study has potential implications for design of a novel class of chemotherapeutic leads functioning as mechanism-based inhibitors of ergosterol biosynthesis to treat neglected tropical diseases.
